US 11,596,660
Application 17/842,406 · Granted Mar 7, 2023
Methods of treating bladder cancer
Estimated expiration
April 13, 2038
11y 146d remaining
Earliest effective filing
Apr 13, 2018
+ 20 years
Apr 13, 2038
PTA +0d
Apr 13, 2038
TD cap (US 12,370,229)
Apr 13, 2038
Final
Apr 13, 2038
- Earliest effective filing
- Apr 13, 2018
- + 20 years
- Apr 13, 2038
- PTA +0d
- Apr 13, 2038
- TD cap (US 12,370,229)
- Apr 13, 2038
- Final
- Apr 13, 2038
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- June 16, 2022
- Earliest effective filing
- April 13, 2018
- Issue date
- March 7, 2023
- PTA
- 0 days
- Base expiry (before PTA)
- April 13, 2038
April 13, 2018 + 20 years = April 13, 2038
- Continuation of application 17/713,975, filed Apr 5, 2022, issued as US 12,370,229
- Continuation of application 16/605,066, filed Oct 14, 2019, issued as US 11,338,003
- National stage entry of application PCTUS2018027549, filed Apr 13, 2018
- National stage entry of application PCTUS2018027549, filed Apr 13, 2018
- Continuation of application 16/605,066, filed Oct 14, 2019, issued as US 11,338,003
- National stage entry of application PCTUS2018027549, filed Apr 13, 2018
- PRO62/485,805 — Provisional — not used for base term
- PRO62/500,729 — Provisional — not used for base term
- PRO62/500,729 — Provisional — not used for base term
- PRO62/485,805 — Provisional — not used for base term
- PRO62/500,729 — Provisional — not used for base term
- PRO62/485,805 — Provisional — not used for base term
- PRO62/500,729 — Provisional — not used for base term
- PRO62/485,805 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to April 13, 2038 (earliest expiring referenced patent: US 12,370,229)
US 11,338,003· Application 16/605,066Capping patent
Methods of treating bladder cancer with an oncolytic virus
- Filing date
- Oct 14, 2019
- Earliest effective filing
- Apr 13, 2018
- Issue date
- May 24, 2022
- PTA
- +294 days
- Calculated expiration
- Feb 1, 2039
National stage entry of PCTUS2018027549, filed Apr 13, 2018
Apr 13, 2018 + 20y + 294d PTA = Feb 1, 2039
US 12,370,229· Application 17/713,975(from application 17/713,975)Capping patent
Methods of treating bladder cancer
- Filing date
- Apr 5, 2022
- Earliest effective filing
- Apr 13, 2018
- Issue date
- Jul 29, 2025
- PTA
- 0 days
- Calculated expiration
- Apr 13, 2038
Continuation of 16/605,066, filed Oct 14, 2019, issued as US 11,338,003
National stage entry of PCTUS2018027549, filed Apr 13, 2018
National stage entry of PCTUS2018027549, filed Apr 13, 2018
Apr 13, 2018 + 20y = Apr 13, 2038
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 17/842,406 · US 11,596,660
PatentReply compiles the prosecution history behind US 11,596,660: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11596660Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.